• Explore /
  • Poster
  • / Long-term outcomes of patients with HER2+ breast cancer with small-size residual disease (≤ypT1) in the absence of pathological response after trastuzumab-based neoadjuvant chemotherapy and without adjuvant T-DM1: A monocentric retrospective study.

Long-term outcomes of patients with HER2+ breast cancer with small-size residual disease (≤ypT1) in the absence of pathological response after trastuzumab-based neoadjuvant chemotherapy and without adjuvant T-DM1: A monocentric retrospective study.

Abstract Poster

Authors

null

Ludovic Doucet

ICO, Nantes Saint-Herblain, France

Ludovic Doucet , Camille Moreau-Bachelard , Carole Gourmelon , Marie Robert , Dominique Berton , Emmanuelle Bourbouloux , Catherine Guerin , Cyriac Blonz , Nicole Andrieux , Mario Campone , Jean-Sebastien Frenel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Citation

J Clin Oncol 38: 2020 (suppl; abstr 589)

DOI

10.1200/JCO.2020.38.15_suppl.589

Abstract #

589

Poster Bd #

81

Abstract Disclosures

Similar Posters

First Author: Roberto Antonio Leon-Ferre

First Author: Sonya Chew

First Author: Massimo Di Iorio

First Author: Kai Conrad Cecil Johnson